Breadcrumb Home Studies Studies Search Filter Research Area AllBrain and Mental HealthCure and ImmunotherapyTherapeuticsTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis Completed Sort Study Number AscStudy Number Desc Submit Search Showing 6 studies. IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2050: CREATE DAIDS Number 39208 Research Area Therapeutics Study Status Open to Accrual IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics
IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
